Thursday, June 5, 2025
News Health
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
HealthNews
No Result
View All Result
Home Health News

Vestibular Therapy in ED Shows Promise for Dizziness

March 31, 2025
in Health News
Share on FacebookShare on Twitter


TOPLINE:

Emergency department vestibular rehabilitation therapy (ED-VeRT) was feasible and reduced symptoms and vestibular activity in patients who presented with dizziness in the ED, a new study reported.

METHODOLOGY:

  • This nonrandomized clinical trial enrolled participants (median age, 52 years; 58% women; 49% White) presenting with dizziness or vertigo at an ED in Chicago from 2021 to 2023.
  • Participants received either ED-VeRT (n = 55), delivered by physical therapists using a protocolized diagnostic classification algorithm, or usual care (n = 51), as determined by the treating physician.
  • The primary outcome was the change in the Dizziness Handicap Inventory (DHI) score, and secondary outcomes were the change in the Vestibular Activities Avoidance Inventory-9 (VAAI-9) score, patient-reported medication use in the past 24 hours, and ED visit characteristics over 3 months of follow-up.

TAKEAWAY:

  • Among the 366 patients screened, 125 were enrolled, with 105 (84%) retained in longitudinal data collection, highlighting the feasibility of ED-VeRT.
  • Among the participants receiving ED-VeRT, diagnostic classifications included benign paroxysmal positional vertigo (37.1%), triggered undifferentiated dizziness (22.6%), spontaneous undifferentiated dizziness (22.6%), and unilateral peripheral hypofunction (14.5%).
  • At 3 months, participants receiving ED-VeRT had lower DHI scores (mean difference, −1.68; 95% CI, −11.30 to 7.90) and VAAI-9 scores (mean difference, −2.27; 95% CI, −8.40 to 3.86) than those receiving usual care.
  • Compared with participants receiving usual care, those receiving ED-VeRT had higher rates of discharge (66% vs 75%) and lower diagnostic imaging use (CT brain: 71% vs 56%).

IN PRACTICE:

“This present study represents a notable departure from the extant dizziness literature as it focuses on the patient-oriented outcome of dizziness-related disability,” the authors wrote. “The data generated from this pilot study may subsequently inform the design and sample size calculations of a multisite randomized clinical trial of ED vestibular therapy for dizziness and vertigo,” they added.

SOURCE:

The study was led by Howard S. Kim, MD, MS, Northwestern University Feinberg School of Medicine, Chicago. It was published online on February 14, 2025, in JAMA Network Open.

LIMITATIONS:

The study was limited by its nonrandomized design and unmeasured variables that were not accounted for in the analysis. Participants receiving ED-VeRT reported higher baseline symptom scores than those receiving usual care. The sample size was small, and analyses were potentially underpowered. Additionally, a single physical therapist performed most vestibular evaluations, potentially limiting the generalizability of the findings.

DISCLOSURES:

The study received support from the Davee Foundation and the Agency for Healthcare Research and Quality (grant R01HS027426). Howard S. Kim, MD, MS, reported receiving a stipend from the American Medical Association as a deputy editor for JAMA Network Open, outside the submitted work.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.



Source link : https://www.medscape.com/viewarticle/emergency-department-vestibular-therapy-shows-promise-2025a10007n6?src=rss

Author :

Publish date : 2025-03-31 12:06:00

Copyright for syndicated content belongs to the linked Source.

Previous Post

Quantum eavesdropping could work even from inside a black hole

Next Post

Corcept’s Ovarian Cancer Drug Cuts Disease Progression in Study, Shares Jump

Related Posts

Health News

SGLT2 Inhibitor Shows Promise as MASH Treatment

June 4, 2025
Health News

HELP Committee Supports Reauthorizing FDA Program to Streamline Review of OTC Drugs

June 4, 2025
Health News

Texas Hospital That Discharged Woman With Doomed Pregnancy Violated Law, Probe Finds

June 4, 2025
Health News

Viral Immunotherapy Reduces Recurrences in Early Prostate Cancer

June 4, 2025
Health News

Disparities in Myasthenia Gravis Care

June 4, 2025
Health News

Win for Added Relacorilant in Platinum-Resistant Ovarian Cancer

June 4, 2025
Load More

SGLT2 Inhibitor Shows Promise as MASH Treatment

June 4, 2025

HELP Committee Supports Reauthorizing FDA Program to Streamline Review of OTC Drugs

June 4, 2025

Texas Hospital That Discharged Woman With Doomed Pregnancy Violated Law, Probe Finds

June 4, 2025

Viral Immunotherapy Reduces Recurrences in Early Prostate Cancer

June 4, 2025

Disparities in Myasthenia Gravis Care

June 4, 2025

Win for Added Relacorilant in Platinum-Resistant Ovarian Cancer

June 4, 2025

Dead Sea Scrolls analysis may force rethink of ancient Jewish history

June 4, 2025

Mental Health and Myasthenia Gravis

June 4, 2025
Load More

Categories

Archives

June 2025
MTWTFSS
 1
2345678
9101112131415
16171819202122
23242526272829
30 
« May    

© 2022 NewsHealth.

No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health

© 2022 NewsHealth.

Go to mobile version